sefulness of medroxyprogesterone acetate in the follicular phase for ovarian donors to prevent premature luteinization - Prevent premature luteinization

INSTITUTO VALENCIANO DE INFERTILIDAD (IVI)0 个研究点目标入组 318 人开始时间: 2017年6月27日最近更新: 2019年12月10日

试验速览

暂无简介。

•Female subjects between 18-35 years old
•- No personal or family history of interest
•- Sign Informed Consent
•- From the medical point of view:
•Body mass index between 18-28 kg / m2
•Uterus and normal ovaries, without organic pathology
•Non-polycystic ovaries
•Count of antral follicles> 12 in the sum of the two ovaries
•Normal karyotype
•Negative screening for infectious diseases (Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus and Syphilis)
•General Analytic with hemogram, hemostasis and biochemistry with parameters within normality.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 318
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Simultaneous participation in another clinical study
•- Participation in another clinical study 2 months before inclusion in the present study that could affect the objectives of the study
•- Any systemic or metabolic disorder that contraindicates the use of gonadotrophins.
•- History of thrombophlebitis and thromboembolic phenomena and HT
•- Known hypersensitivity to AMP or its excipients
•- Any motive that implies exclusion from the oocyte donation program
•- Suspect or evidence of mammary malignancy or hormone-dependent genitalia
•- Known infection with human immunodeficiency virus, active virus of hepatitis B or C.

发起方

INSTITUTO VALENCIANO DE INFERTILIDAD (IVI)